Autobahn Therapeutics starts trial of ABX-002 for major depressive disorder in adults
Autobahn Therapeutics initiated AMPLIFY Phase II trial assessing ABX-002 as adjunctive treatment for MDD in adults. The placebo-controlled, double-blind study involves 230 participants and evaluates tolerability, safety, efficacy, and pharmacodynamic effects alongside existing SSRI or SNRI treatments. Primary success measure is HAMD-17 change after six weeks. Secondary endpoints include HAMD-29 and Montgomery–Åsberg Depression Rating Scale. Topline data expected in H2 next year, with another Phase II trial for bipolar disorder depression planned by year-end.
Reference News
Autobahn Therapeutics initiated AMPLIFY Phase II trial assessing ABX-002 as adjunctive treatment for MDD in adults. The placebo-controlled, double-blind study involves 230 participants and evaluates tolerability, safety, efficacy, and pharmacodynamic effects alongside existing SSRI or SNRI treatments. Primary success measure is HAMD-17 change after six weeks. Secondary endpoints include HAMD-29 and Montgomery–Åsberg Depression Rating Scale. Topline data expected in H2 next year, with another Phase II trial for bipolar disorder depression planned by year-end.